iodine i 131 iopofosine

Drug Overview

iodine i 131 iopofosine is an advanced, highly specialized medication used in the field of cancer care. It is not a standard, everyday medicine. Instead, it is currently being studied in clinical trials as a potential new option for patients with hard-to-treat cancers, particularly certain blood cancers and brain tumors. This medication acts as a “Smart Drug” by delivering targeted radiation directly to cancer cells while largely sparing healthy tissues.

• Generic Name: Iopofosine I 131 (also widely known in research as CLR 131).
• US Brand Names: None yet. It is an investigational drug, meaning it does not have a commercial brand name for general public use at this time.
• Drug Class: Phospholipid Drug Conjugate (PDC) / Targeted Radiotherapeutic.
• Route of Administration: Intravenous (IV) infusion (injected directly into a vein).
• FDA Approval Status: Currently investigational. It is not yet fully FDA-approved for standard commercial use. However, it has received special statuses from the FDA to speed up its development, including “Breakthrough Therapy,” “Fast Track,” “Orphan Drug,” and “Rare Pediatric Drug” designations.

What Is It and How Does It Work? (Mechanism of Action)

Iopofosine I 131 is considered a Targeted Therapy and a Smart Drug. To understand how it works, it helps to think of the drug as a microscopic delivery vehicle carrying a tiny radioactive payload.

At the molecular level, cancer cells grow and divide rapidly. Because of this fast growth, cancer cells have an altered metabolism and require different building blocks than healthy cells. One of the things they need more of is certain fats called lipids. As a result, cancer cells develop special entryways on their outer surface known as “lipid rafts.” Healthy cells have very few of these lipid rafts.

Here is how the drug exploits this difference to fight cancer:

1. The Disguise: Iopofosine I 131 is a synthetic molecule designed to look exactly like the natural lipids that cancer cells crave (specifically, it is an alkyl phosphocholine analog).
2. Entering the Cell: Because it looks like food to the tumor, the drug selectively homes in on the cancer cells and easily passes through their lipid raft entryways. Once inside, it interacts with specific survival pathways in the cell (known as the PI3K/Akt pathway) that normally help the cancer grow.
3. Delivering the Payload: The “I-131” part of the drug’s name stands for Iodine-131. This is a radioactive element attached to the lipid vehicle. Because the cancer cell takes in the drug and breaks it down very slowly, the radioactive iodine gets trapped inside.
4. Destroying the Tumor: Once trapped inside the malignant cell, the Iodine-131 gives off safe, localized “beta radiation.” This radiation breaks the cancer cell’s DNA apart from the inside out, causing the cell to die without causing major damage to the surrounding healthy tissues.

FDA-Approved Clinical Indications

Because iopofosine I-131 is an investigational agent, it does not currently have standard FDA-approved indications for routine clinical practice. However, based on promising clinical trials, it is being actively studied for the following uses:

• Oncological Uses (In Clinical Trials):
  • Waldenström Macroglobulinemia (WM): For patients whose disease has returned (relapsed) or has not responded to multiple previous treatments.
  • Pediatric High-Grade Glioma (pHGG): A rare and aggressive type of brain cancer in children, adolescents, and young adults.
  • Multiple Myeloma (MM): For relapsed or hard-to-treat cases.
  • Central Nervous System (CNS) Lymphoma: Cancers affecting the brain and spinal cord.
  • Head and Neck Cancers: Used in combination with standard external beam radiation therapy.
• Non-oncological Uses:
  • Currently, there are no non-oncological uses. This drug is specifically designed to target and destroy cancer cells.

Dosage and Administration Protocols

Because this is a radioactive targeted therapy, it is given in specialized medical centers by trained radiation oncology or nuclear medicine teams. It is not a pill you take at home.

Clinical Efficacy and Research Results

Recent clinical studies from 2024 and 2025 have shown highly encouraging results for iopofosine I-131.

• Waldenström Macroglobulinemia: In the pivotal Phase 2 study known as CLOVER-WaM (reporting in late 2024 and 2025), patients who had already failed multiple other therapies showed an Overall Response Rate (ORR) of 83.6%. Furthermore, 58.2% of patients experienced a “major response,” meaning their disease burden was significantly reduced. At a follow-up of nearly 9 months, an estimated 72% of responding patients remained progression-free.
• Pediatric Brain Cancer: In the 2025 CLOVER-2 trial for children and young adults with highly aggressive relapsed brain tumors (gliomas), the drug showed meaningful survival benefits. For patients receiving higher total doses, the average progression-free survival (the time the tumor stopped growing) was around 5.4 to 8.1 months, with overall survival averaging between 8.6 and 11.5 months. Some patients saw their tumors shrink by more than 50% and remained alive for well over 18 months, which is a major medical milestone for this specific, difficult disease.

Safety Profile and Side Effects

Black Box Warning: As an investigational drug, iopofosine I-131 does not yet carry an official FDA Black Box Warning. However, because it delivers radiation, strict handling guidelines apply, and it is known to lower blood cell counts.

The safety profile of this drug is generally considered favorable compared to traditional chemotherapy because the radiation is highly targeted. It has not caused any heart, kidney, liver, or nerve damage (neuropathy) in clinical trials.

Common Side Effects (>10%):

Most side effects are related to the blood, because the bone marrow is sensitive to radiation.

• Thrombocytopenia (80%): Low blood platelet counts, which can lead to easy bruising or bleeding.
• Neutropenia (69%): Low white blood cell counts, which increase the risk of catching an infection.
• Anemia (45%): Low red blood cells, which can cause tiredness, weakness, and shortness of breath.
• Infections (12%): Due to the lowered immune system response.

Serious Adverse Events:

• Severe drops in blood counts (Grade 3 or 4 myelosuppression).
• Severe infections or bacterial sepsis (very rare, but serious).

Management Strategies:

Medical teams closely monitor patients’ blood counts through routine blood tests. If blood counts drop too low, doctors can delay the next dose, reduce the amount of the drug given, or provide supportive care. This care can include blood transfusions to replace red cells or platelets, and special medications called “growth factors” to help the bone marrow create new white blood cells quickly.

Research Areas

While iopofosine I 131 is primarily being tested on its own as a single treatment, there is exciting ongoing research looking into how it can be combined with other therapies. Scientists are exploring whether using this smart radiotherapy alongside modern Immunotherapy could boost the body’s natural immune response against cancer. Furthermore, researchers are testing it alongside traditional external beam radiation for head and neck cancers to see if the two types of radiation can work together to shrink tumors that are otherwise too difficult to operate on.

Patient Management and Practical Recommendations

To ensure safety and achieve the best possible results, patients must follow strict guidelines before, during, and after receiving this targeted radiotherapy.

Pre-treatment Tests to be Performed:

• Complete Blood Count (CBC): To ensure your bone marrow is healthy enough to handle the treatment.
• Organ Function Tests: Routine blood tests to check your liver and kidneys.
• Pregnancy Test: A negative pregnancy test is strictly required for women of childbearing age, as radiation can cause severe harm to an unborn baby.
• Baseline Imaging: PET, CT, or MRI scans to map out the exact size and location of the cancer.

Precautions During Treatment:

Because the drug contains radioactive iodine, you will give off a small amount of radiation for a short time after your infusion. You must follow the isolation guidelines given by your hospital’s radiation safety officer.

“Do’s and Don’ts” List:

• DO drink plenty of water (stay well-hydrated) for a few days after your infusion to help your kidneys flush the broken-down drug from your system.
• DO use a separate bathroom if possible, and flush the toilet twice after every use for the first few days.
• DO wash your hands thoroughly with soap and water frequently.
• DON’T have close physical contact with pregnant women, infants, or small children for the specific number of days recommended by your medical team.
• DON’T start any new medicines or herbal supplements without checking with your oncologist first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Iopofosine I 131 is an investigational diagnostic and therapeutic agent and is not currently approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general clinical use. It is available only through participation in approved clinical trials or expanded access programs. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, side effect management, and eligibility for clinical trials.